Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

被引:0
作者
Huang, Si-Man [1 ,2 ,3 ]
Wan, Chao-Ling [1 ,2 ,3 ]
Cao, Han-Yu [1 ,2 ,3 ]
Li, Yan-Yan [1 ,2 ,3 ]
Qian, Chong-Sheng [1 ,2 ,3 ]
Zhou, Hai-Xia [1 ,2 ,3 ]
Xu, Ming-Zhu [1 ,2 ,3 ]
Hu, Xiao-Hui [1 ,2 ,3 ]
Dai, Lan [1 ,2 ,3 ]
Dai, Hai-Ping [1 ,2 ,3 ]
Xue, Sheng-Li [1 ,2 ,3 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, 188 Shizi St, Suzhou 215006, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[3] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
来源
CLINICAL CASE REPORTS | 2023年 / 11卷 / 12期
关键词
B-ALL; CD22; inotuzumab ozogamicin; MRD positive; relapsed and refractory; ADULTS;
D O I
10.1002/ccr3.8289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B-ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.
引用
收藏
页数:5
相关论文
empty
未找到相关数据